Company profile: Faraday Pharma
1.1 - Company Overview
Company description
- Provider of early-stage therapeutics targeting ischemia-reperfusion injury, led by FDY-5301, a sodium iodide formulation in Phase 3 to reduce injury after myocardial infarction and potentially decrease heart failure and cardiovascular death. Advancing FDY-8801 for cachexia, and running Iocyte AMI-3 Phase 3 in anterior STEMI PCI; Iocyte AMI Phase 2 completed showing cardiac and inflammatory biomarker reductions.
Products and services
- FDY-5301: A Phase 3 sodium iodide formulation engineered to reduce ischemia‑reperfusion injury following myocardial infarction, potentially decreasing heart failure incidence and cardiovascular death
- Iocyte AMI-3: A Phase 3 clinical trial architected to assess FDY-5301’s efficacy and safety in reducing heart failure and cardiovascular death in anterior STEMI patients undergoing primary PCI
- FDY-8801: An investigational agent produced to target cachexia-related muscle wasting associated with cancer and other chronic diseases, in a field with no FDA‑approved medications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Faraday Pharma
Omni Biopharma
HQ: United States
Website
- Description: Provider of Alpha-1 antitrypsin (AAT)-based therapeutics, developing alternative uses of AAT for various medical treatments and advancing recombinant forms of AAT for therapeutic applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omni Biopharma company profile →
Recursion
HQ: United States
Website
- Description: Provider of a machine learning-driven drug discovery platform (Recursion OS), digital chemistry tools (MatchMaker), and an on-premise supercomputer (BioHive-1) to map complex biology and rapidly advance potential therapeutics; also collaborates with Bayer, Roche & Genentech, NVIDIA, Tempus, and Enamine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recursion company profile →
Sophos Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical medicines and drugs for the treatment of mucositis and prostate and breast oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sophos Biotech company profile →
Idorsia
HQ: Switzerland
Website
- Description: Provider of innovative biopharmaceutical therapies and resources, including daridorexant (QUVIVIQ), a dual orexin receptor antagonist for chronic insomnia, aprocitentan (TRYVIO/JERAYGO), an oral dual endothelin receptor antagonist for resistant hypertension, and a medical information and educational portal for healthcare professionals and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idorsia company profile →
Harvard Apparatus Regenerative Technology
HQ: United States
Website
- Description: Provider of regenerative implant technologies using Cellspan scaffolds seeded with patients’ stem cells, including esophageal and bronchial implants to repair tubular structures and reduce complications; applications for digestive tract disorders and patch technologies for reproductive tract disorders; and a consumer medicine division offering longevity products for Asia’s aging population.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harvard Apparatus Regenerative Technology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Faraday Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Faraday Pharma
2.2 - Growth funds investing in similar companies to Faraday Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Faraday Pharma
4.2 - Public trading comparable groups for Faraday Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →